Eisenberger, Ute (2011). [Renal transplantation - new developments]. Therapeutische Umschau, 68(12), pp. 687-92. Bern: Huber 10.1024/0040-5930/a000231
Full text not available from this repository.Renal transplantation has become an established option for renal replacement therapy in many patients with end stage renal disease. Living donation is a possibility for timely transplantation, hampered in 20 % of all possible donors and recipients byincompatible blood groups. AB0-incompatible renal transplantation overcomes this hurdle with acceptable allograft survival compared to conventional living-donor renal transplantation. During the last 10 years, the number of patients awaiting renal transplantation older than 65 years has nearly doubled. The decision to transplant those patients and their medical treatment is a growing challenge in transplantation. On the other hand donor age is increasing with potential negative consequences for long-term outcome of organ function. Antibody-mediated humoral rejection have been identified lately as an important cause for allograft failure during long-term follow up of renal transplant patients. New immunological methods to detect donor-specific antibodies, like solid-phase assays (Luminex®), have increased the knowledge and understanding of humoral rejection processes. This will lead hopefully to modified immunosuppressive strategies to minimize organ failure due to chronic rejection.
Item Type: |
Journal Article (Further Contribution) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension |
UniBE Contributor: |
Eisenberger, Ute |
ISSN: |
0040-5930 |
Publisher: |
Huber |
Language: |
German |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:17 |
Last Modified: |
05 Dec 2022 14:04 |
Publisher DOI: |
10.1024/0040-5930/a000231 |
PubMed ID: |
22139983 |
URI: |
https://boris.unibe.ch/id/eprint/5347 (FactScience: 210087) |